April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Visual Improvement in Central Retinal Vein Occlusion (crvo) Following Intravitrel Injections of Bevacizumab
Author Affiliations & Notes
  • L. de Polo
    Department of Clinical Science "Luigi Sacco, Eye Clinic, Sacco Hospital,University of Milan,Italy, Milan, Italy
  • M. Cigada
    Department of Clinical Science "Luigi Sacco, Eye Clinic, Sacco Hospital,University of Milan,Italy, Milan, Italy
  • G. Staurenghi
    Department of Clinical Science "Luigi Sacco, Eye Clinic, Sacco Hospital,University of Milan,Italy, Milan, Italy
  • Footnotes
    Commercial Relationships  L. de Polo, None; M. Cigada, None; G. Staurenghi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3571. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. de Polo, M. Cigada, G. Staurenghi; Visual Improvement in Central Retinal Vein Occlusion (crvo) Following Intravitrel Injections of Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3571.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the visual acuity improvement inresponse to intravitreal injections of bevacizumab in central retinal vein occlusion (CRVO).

Methods: : Retrospective consecutive non comparative case series of 22 eyes of 22 patients affected by CRVO were enrolled; mean age was 64 years (range 43-85 years);10 males and 12 females. At baseline ETDRS mean visual acuity was 20/100 (range 20/400-20/40). No previous treatment occured. A complete clinical examination, including optical coherence tomography (OCT), was carried out at baseline and after each injection of bevacizumab and at all follow-up visits. Digital fluorescein angiography (HRA) was performed at baseline and each 6 months. Mean number of injections was 3.5 (range1-12) during a mean follow-up of 28 months (range 12-41). Intra-vitreal injections of bevacizumab (1.25 mg/ 0.05 ml) were given at baseline and after OCT retinal Thickness increase or visual acuity reduction.

Results: : Final ETDRS mean visual acuity was 20/50 (range 20/200-20/20).Visual acuity improvement was less than 15 ETDRS letters for 55% of patients and more than 15 ETDRS letters for 45% of patients. No visual acuity reduction occured. A Fisher’s Exact Test for Count Data demonstrates that the frequency, the number of injections and the follow-up lenght are not statistical significant to demonstrate a visual improvement. Using the Analysis of Variance (ANOVA) the baseline value of visual acuity has a statistically significant effect on visual acuity (P=0.03). No adverse events occured.

Conclusions: : In response to intravitreal injections of bevacizumab during 28 months, a statistically significant improvement in visual acuity occurs depending to the baseline visual acuity and it is independent from the number and the frequency of injections. Further clinical trials are needful to evaluate a larger number of patients and a longer follow-up.

Keywords: vascular occlusion/vascular occlusive disease • edema • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×